• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Tailor-made cleavage site attenuates influenza B

tetano

Editor, Senior Moderator
Expert Rev Vaccines. 2012 Feb;11(2):159-61.
Tailor-made cleavage site attenuates influenza B.
Saelens X.
Source

Department for Molecular Biomedical Research, VIB, 9000 Ghent, Belgium and Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium and Technologiepark 927, B-9052 Zwijnaarde (Ghent), Belgium. xavier.saelens@dmbr.vib-ugent.be.
Abstract

Evaluation of: Stech J, Garn H, Herwig A et al. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J. Infect. Dis. 204(10), 1483-1490 (2011). Influenza B viruses contribute significantly to human influenza. The circulation of two antigenically divergent lineages of this virus can reduce the efficacy of licensed influenza vaccines. A novel live-attenuated influenza B vaccine candidate has been generated by creating a virus that strictly requires elastase activity for the accurate proteolytic maturation of its hemagglutinin. This mutant influenza B virus grows to high titers in vitro and is strongly attenuated in mice, yet it induces a robust protective immune response in this host. The findings on this tamed influenza B virus and its potential prospects are discussed.

PMID:
22309664
[PubMed - in process]

Free full text

http://www.ncbi.nlm.nih.gov/pubmed/22309664
 
Back
Top Bottom